Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A

Journal of the National Cancer Institute

Volumn 88, Issue 23, 1996, Pages 1770-1776

  Ciardiello, Fortunato ^a   Damiano, Vincenzo ^b   Bianco, Roberta ^b   Bianca, Caterina ^b   Fontanini, Gabriella ^b   De Laurentiis, Michelino ^b   De Placido, Sabino ^b   Mendelsohn, John ^b   Raffaele Bianca, A ^b   Tortora, Giampaolo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER GROWTH; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 16144362509     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.23.1770     Document Type: Article

References (40)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
2. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 37 patients and review of 3009 patients. Breast Cancer Res Treat 1994;29:41-9.
3. Mendelsohn J. Potential clinical applications of anti-EGF receptor monoclonal antibodies. Cancer Cells 1989;7:359-62.
4. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994;29:127-38.
5. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984;259:7755-60.
6. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605-11.
7. Modjtahedi H, Eccles S, Box G, Styles J, Dean C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 1993;67:254-61.
8. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-7.
9. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1992;53: 4637-42.
10. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, et al. Antitumor effects of doxorubicin in combination with antiepidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-33.
11. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al. Phase I and imaging trial of indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma [see comment citation in Medline]. J Natl Cancer Inst 1991;83:97-104.
12. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
13. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 1990;59:971-1005.
14. Cho-Chung YS. Role of cAMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 1990;50:7093-100.
15. Tortora G, Ciardiello F, Ally S, Clair T, Salomon DS, Cho-Chung YS. Site-selective 8-chloro-adenosine 3′,5′-monophosphate inhibits transformation and transforming growth factor alpha production in Ki-ras-transformed rat fibroblasts. FEES Lett 1989;242:363-7.
16. Ciardiello F, Tortora G, Kim N, Clair T, Ally S, Salomon DS, et al. 8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. J Biol Chem 1990;265:1016-20.
17. Ciardiello F, Pepe S, Bianco C, Baldassarre G, Ruggiero A, Bianco C, et al. Down-regulation of RI alpha subunit of the cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int J Cancer 1993;53:438-43.
18. Tortora G, Pepe S, Bianco C, Baldassarre G, Budillon G, Clair T, et al. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 1994;9: 3233-40.
19. Pepe S, Ruggiero A, Tortora G, Ciardiello F, Garbi C, Yokozaki H, et al. Flow-cytometric detection of the RI alpha subunit of type I cAMP-dependent protein kinase in human cells. Cytometry 1994;15:73-9.
20. Tortora G, Pepe S, Cirafici AM, Ciardiello F, Porcellini A, Clair T, et al. Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cyclic AMP-dependent protein kinase. Cell Growth Differ 1993;4:359-65.
21. Miller WR, Watson DM, Jack W, Chetty U, Elton RA. Tumor cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat 1993;26:89-94.
22. Tagliaferri P, Katsaros D, Clair T, Ally S, Tortora G, Neckers L, et al. Synergistic inhibition of growth of breast and colon human cancer cell line by site-selective cyclic AMP analogues. Cancer Res 1988;48:1642-50.
23. Ally S, Clair T, Katsaros D, Tortora G, Yokozaki H, Finch RA, et al. Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate. Cancer Res 1989;49:5650-5.
24. Rohlff C, Clair T, Cho-Chung YS. 8-Cl-cAMP induces down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 1993;268:5774-82.
25. Pinto A, Aldinucci D, Gattei V, Zagonel V, Tortora G, Budillon A, et al. Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site selective 8-chloroadenosine 3′,5′-cyclic monophosphate. Proc Natl Acad Sci U S A 1992;89:8884-8.
26. Tortora G, Ciardiello F, Pepe S, Tagliaferri P, Ruggiero A, Bianco C, et al. Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients. Clin Cancer Res 1995;1:377-84.
27. Ciardiello F, Damiano V, Bianco C, di Isemia, Ruggiero A, Caraglia M, et al. Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. Clin Cancer Res 1995;l:161-7.
28. Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, et al. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996;65:51-6.
29. Fontanini G, Macchiarini P, Pepe S, Ruggiero A, Hardin M, Bigini D, et al. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer 1992;70:1520-7.
30. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-I tat product: inhibition of KS-like lesions by tissue inhibition of metalloproteinase-2. AIDS 1994;8:1237-44.
31. Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, et al. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factors antisense oligonucleotides. Clin Cancer Res 1996;2:601-9.
32. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley, 1981.
33. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 163-70.
34. Ciardiello F, Tortora G, Bianco C, Selvam MP, Basolo F, Fontanini G, et al. Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene 1994;9: 291-8.
35. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31.
36. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [see comment citations in Medline]. N Engl J Med 1995; 333:1757-63.
37. Mendelsohn J, Lippman ME. Principles of molecular cell biology of cancer: growth factors. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol 2. 4th ed. Philadelphia: Lippincott, 1993:114-33.
38. Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook PW, Ramsey GW, et al. Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem 1994;269:22817-22.
39. Normanno N, Selvam MP, Qi C, Saeki T, Johnson G, Kim N, et al. Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells. Proc Natl Acad Sci U S A 1994; 91:2790-4.
40. Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, et al. Phase I studies of anti-epidermal growth factor receptor (EG/FR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc ASCO 1996;15:1381.